Joseph Cinderella, MD
Interventional Cardiology · Salisbury, MDNPI 1407848609
Payments from drug & device makers
Across 474 payments — averaging $150.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$41K
- Lilly USA, LLC$20K
- Medtronic$2K
- Abbott$901
- Novartis$831
- Boston Scientific$749
- plus $5K from 32 others
What the payments were for
- Consulting fees$450%
- Speaking & faculty fees$58,56982%
- Travel & lodging$1,5112%
- Food & beverage$11,31716%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 81 | $41,310 |
| Lilly USA, LLC | 16 | $20,420 |
| Medtronic(2 entities) | 60 | $2,371 |
| Abbott | 14 | $901 |
| Novartis | 35 | $831 |
| Boston Scientific | 34 | $749 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $642 |
| Amgen | 22 | $638 |
| AstraZeneca | 31 | $633 |
| E.r. Squibb & Sons, L.L.C. | 28 | $476 |
| Pfizer | 22 | $375 |
| Scpharmaceuticals Inc. | 7 | $332 |
| Lexicon Pharmaceuticals, Inc. | 7 | $238 |
| Chiesi USA, Inc. | 7 | $229 |
| Johnson & Johnson | 14 | $220 |
| Abiomed | 6 | $205 |
| Esperion Therapeutics, Inc. | 7 | $123 |
| Merck | 8 | $114 |
| Amarin Pharma, Inc. | 4 | $78 |
| Bayer | 4 | $77 |
| Sanofi-aventis U.S. LLC | 3 | $61 |
| Novo Nordisk | 3 | $58 |
| Cardinal Health 200 LLC | 4 | $50 |
| ZOLL Circulation Inc | 2 | $50 |
| Edwards Lifesciences | 3 | $44 |
| Philips North America LLC | 2 | $40 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Irhythm Technologies, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $32 |
| Cardiovascular Systems Inc. | 2 | $28 |
| Gilead | 2 | $25 |
| Atricure, Inc. | 1 | $23 |
| Preventice Services, LLC | 1 | $22 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Braemar Manufacturing, LLC | 1 | $13 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$59,137
- COREVALVE EVOLUT R$312
- MitraClip$260
- FUROSCIX$255
- ONYX FRONTIER$226
- LEQVIO$181
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$143
- Resolute$132
- TRICLIP$129
- Impella$128
- Inpefa$125
- Watchman$124
- Repatha$121
- KENGREAL$116
- XIENCE SKYPOINT$100
How this compares
$71,556 in reported general payments places this provider in the 75th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $94,429 |
| JardianceEmpagliflozin | 81 | $85,279 |
| EntrestoSacubitril/Valsartan | 54 | $71,236 |
| XareltoRivaroxaban | 29 | $34,199 |
| Repatha SureclickEvolocumab | 11 | $9,001 |
| Metoprolol Succinate | 286 | $4,348 |
| Nitroglycerin | 101 | $2,010 |
| Amlodipine Besylate | 270 | $1,754 |
| Warfarin Sodium | 104 | $1,324 |
| Atorvastatin Calcium | 115 | $1,252 |
| Losartan Potassium | 112 | $1,246 |
| Valsartan | 31 | $1,206 |
| Spironolactone | 129 | $963 |
| Ezetimibe | 18 | $931 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $375 | $94,42997 claims |
| Boehringer IngelheimJardiance | $41,310 | $85,27981 claims |
| NovartisEntresto | $831 | $71,23654 claims |
| Johnson & JohnsonXarelto | $220 | $34,19929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Salisbury
- Steven HearneSalisbury$2.6M
- Jeffrey EthertonSalisbury$11K
- Mark TreuthSalisbury$8K
- Christian BoundsSalisbury$7K
- John WangBaltimore$6.4M
- Matthew VossBaltimore$2.6M
- Aloke FinnBaltimore$1.8M
- William HerzogColumbia$954K
- Michael ChenRockville$679K
- Vinay SatwahGreenbelt$679K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.